Collaboration to Ensure Efficient Workflows for Biopharmaceutical Characterization

USA: Automated Biotherapeutic Characterization Collaboration to Ensure Efficient Workflows for Biopharmaceutical Characterization

22.04.2021Editor: Alexander Stark

A collaboration between Waters and Genovis aims at developing and marketing complete routine biopharmaceutical characterization workflows based on the Waters Bio Accord LC-MS System, Andrew+ pipetting robot and Genovis' Smart Enzymes.

Related Company

Waters Corporation

The collaboration between Genovis and Waters is among others based on the Bio Accord system.
(Bild: Waters)

Milford/USA — The goal of the collaboration between Waters and Genovis is to develop automated workflows for the rapid and consistent characterization of critical quality attributes (CQAs) of monoclonal antibodies (mAbs) and other protein-based drugs in bioprocess development, formulation, stability testing and quality control (QC). The workflows in development are based on the pairing of the Waters Bio Accord LC-MS System, Andrew+ pipetting robot and Genovis Smart Enzymes and will focus on addressing the application needs of GxP laboratories in the following areas.

One issue that is to be solved by the collaboration is the bottleneck created by up-front sample preparation. This is largely due to the number of manual steps involved and the outmoded technology by which samples are readied for analysis. By combining Genovis’ Smart Enzymes with automation, liquid chromatography/time-of-flight mass spectrometry and application-specific software workflows from Waters, the companies intend to increase productivity of biotherapeutic analysis.

The enzymatic workflows that we will be jointly developed are to help customers in their efforts to bring safe and novel therapeutics to patients, faster.

Unfold for details of your consent

Stand vom 23.03.2021

Naturally, we always handle your personal data responsibly. Any personal data we receive from you is processed in accordance with applicable data protection legislation. For detailed information please see our privacy policy.

Consent to the use of data for promotional purposes

I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planckstr. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here

Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.

In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here.

Right of revocation

I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://support.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.

(ID:47364996)

USA: Automated Biotherapeutic Characterization Collaboration to Ensure Efficient Workflows for Biopharmaceutical Characterization

Subscribe to the newsletter now

Don't Miss out on Our Best Content

Consent to the use of data for promotional purposes